COATS LONNEL — SEC Form 4 filings
SEC reporting owner CIK 1612528. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-10.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-12 to 2026-06-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 1 filing — 19,824 shares, $1,869,658 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 9,824 shares @ $94.87 ($932,003) in Blueprint Medicines Corp, filed 2024-11-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) | Director | 4 | — | 4 legs · 19,824 sh · $1,869,658 | 17 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | Chief Executive Officer, Director | 2 | — | — | 9 |
| Verve Therapeutics, Inc. (VERV) | Director | 3 | — | — | 4 |
| Relay Therapeutics, Inc. (RLAY) | Director | 2 | — | — | 2 |
Form 4 filings — COATS LONNEL
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-10 | 4 | Relay Therapeutics, Inc. (RLAY) | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | Relay Therapeutics, Inc. (RLAY) | Grant/award (A): 207,931 (derivative) @ $0 | EDGAR |
| 2025-07-28 | 4 | Verve Therapeutics, Inc. (VERV) | Disposition to issuer (D): 136,139 (derivative) · Disposition to issuer (D): 42,200 (derivative) | EDGAR |
| 2025-07-21 | 4 | Blueprint Medicines Corp (BPMC) | Disposition to issuer (D): 6,144 · Disposition to issuer (D): 11,818 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 4,875 (derivative) · Disposition to issuer (D): 3,188 (derivative) · +4 more | EDGAR |
| 2025-06-24 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 3,902 @ $12,812 | EDGAR |
| 2025-06-06 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 42,200 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 7,500 @ $69.79 · Option exercise (M): 1,312 @ $76.24 · Sale (S): 4,500 @ $93.15 · Sale (S): 5,287 @ $94.24 · Sale (S): 213 @ $94.99 · Sale (S): 9,824 @ $94.87 · +2 more | EDGAR |
| 2024-06-28 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 136,139 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 2,242 @ $0 · Grant/award (A): 4,570 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Option exercise (M): 33,333 · Option exercise (M): 91,364 · Option exercise (M): 120,383 · Tax withholding (F): 61,371 @ $2.62 · Option exercise (M): 33,333 (derivative) · Option exercise (M): 91,364 (derivative) · +1 more | EDGAR |
| 2024-02-12 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Grant/award (A): 770,420 (derivative) @ $0 · Grant/award (A): 770,420 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1612528 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →